

Konstantynów Łódzki, February 12, 2024

Press Release

Mabion presents ESG Strategy for 2024-2027

Mabion has adopted an ESG Strategy for 2024-2027 setting the Company's goals in the environmental, social and corporate governance areas. Responding to today's most important market and regulatory challenges, the document defines the company's approach and goals in the areas of green transformation, minimizing environmental impact, as well as working conditions, interaction with local communities and responsible management, among others.

"As a company that wants to remain competitive in the international biotechnology market, we need to consider ESG factors in strategic management. Our commitment to the ESG area is driven both by regulatory requirements, such as the CSRD, as well as by the growing expectations of investors, as well as customers and employees. We are convinced that a solidly developed sustainability strategy, taking into account the perspective of all stakeholders, will provide real support for our business operations. Therefore, the ESG strategy for 2024-2027 that we present in this document is closely linked to the business strategy, which means that the individual goals of the business strategy will be supported by the ESG goals. This is particularly important in the context of Mabion's ongoing transformation into a fully integrated contract development and manufacturing organization (CDMO) with a biologics profile, and building a position as a recognizable player in the global contract drug development and manufacturing market," **says Krzysztof Kaczmarczyk, Chief Executive Officer of Mabion S.A.**

Mabion's ESG strategy is divided into three pillars - environmental, social and corporate governance. Within their framework, the Company has developed eight strategic goals, consisting of twenty-three operational goals and specific objectives that will allow the company to monitor the progress of the strategy. The Company has linked its strategic goals to selected UN Sustainable Development Goals and has identified specific tasks that it will carry out within the framework of these goals.

As part of its strategic environmental goals, Mabion will move toward green transformation and minimize its environmental impact. In the social area, Mabion will focus on continuing its efforts to create a safe, friendly and diverse workplace, promote the Company as an attractive employer, and have a positive impact on local communities. As part of its strategic goals in the corporate governance area, the company will continue to implement the highest standards of management, promote responsible business practices throughout the value chain, and build awareness of ESG activities among its stakeholders, including business partners.

Mabion has also set goals for 2024. In the environmental area, among other things, the Company plans to continue measuring its carbon footprint and prepare a decarbonization policy. Among the social goals for 2024, the Company plans to systematize and continue environmental education activities for employees and give them a direction consistent with the strategy, develop and implement a diversity policy, create a social engagement policy, and give a specific goal to social activities and start measuring them. Mabion's corporate goals for this year include joining the Chapter Zero initiative, organizing ESG training for management and the board of directors, and preparing and implementing ESRS-compliant anti-corruption and sponsorship policies.

Mabion's ESG strategy for 2024-2027 is available on the Company's website:

https://www.mabion.eu/wp-content/uploads/2024/02/Strategia-ESG_Mabion.pdf

Contact for media and individual investors

Michał Wierzchowski
+48 531 613 067
+48 22 440 14 40
michal.wierzchowski@ccgroup.pl

Mardoniusz Maćkowiak
+48 605 959 539
+48 22 440 14 40
mardoniusz.mackowiak@ccgroup.pl

Contact for institutional investors and analysts

Piotr Owdziej
+48 697 612 913
+48 22 440 14 40
piotr.owdziej@ccgroup.pl

Katarzyna Mucha
+48 697 613 712
+48 22 440 14 40
katarzyna.mucha@ccgroup.pl

Information about Mabion S.A.

Mabion S.A. (WSE: MAB) is a Polish biopharmaceutical company founded in 2007, which is undergoing a transformation into a fully integrated contract development and manufacturing organization (CDMO) providing a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early stage discovery to commercial manufacturing). Mabion's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances "Drug Substance" and Finished Products "Drug Product"), development of analytical tools (for structural, functional, physicochemical characterization), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The company signed a record contract with Novavax in October 2021 for the commercial production of antigen for the vaccine for COVID-19, which it has since steadily expanded through further services under SOWs (Statements of Work) concluded and annexes signed, adding, among other things, another vaccine product based on the Omicron variant. According to the Strategy, announced in April 2023, the Company's goal is to establish itself as a recognizable player in the global contract manufacturing and contract drug development market and to complete Mabion's full transformation into an integrated biologics CDMO company. Mabion is a public Company, listed on the Warsaw S t o c k Exchange.

For more information about the Company, visit www.mabion.eu